Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Cancer Type/Condition:
Merkel cell carcinoma
Stage/Subtype:
recurrent neuroendocrine carcinoma of the skin
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Pilot Study of Fluorouracil, Leucovorin Calcium, and Oxaliplatin (FOLFOX) With Bevacizumab in Patients With Advanced Neuroendocrine Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCSF-04458
, NCT00227617
2.
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CTCT 06-11
, NCT00493883
3.
Lithium for Low-Grade Neuroendocrine Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Other
Protocol IDs:
CO07203
, NIH R21CA117117-01A2, NCT00501540
4.
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
07-162
, NCT00610129
5.
The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CPTK787/ZK222584
, NCT00627198
6.
Multicenter Study of IMC-A12 in Combination With Depot Octreotide in Patients With Carcinoid or Islet Cell Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP13-0710
, NCT00781911
7.
Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
SU-03272009-2039
, END0008, NCT00947167
8.
Phase I Study of Nelfinavir Mesylate in Patients With Metastatic, Refractory, or Recurrent Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0047
, NCI-P6880, NCT00436735
9.
Phase I Study of Everolimus and Vatalanib in Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0414
, MC0414, NCT00655655
10.
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
08-087
, NCT00804336
11.
Comparison of Standard of Care or Treatment on Protocol
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
INST 0813
, NCT01010334
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
